7:00 a.m. - 4:30 p.m. |
Registration Open |
7:00 a.m. - 8:00 a.m. |
Continental Breakfast |
7:50 a.m. - 8:00 a.m. |
Day One Welcome
Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS] |
8:00 a.m. - 8:20 a.m. |
Patient Perspective: Building a Community of HNL Patients, Coaches and Mentors
Speaker: Michael West |
8:20 a.m. - 9:50 a.m. |
Patient-centric Head and Neck Care
Moderator: Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]
- Comprehensive Rehabilitation of the Head and Neck Patient
- Heather Starmer, MA, CCC-SLP, BCS-S, Stanford University, Stanford, California [SLP]
- Oral/Dental Needs in HNC Survivors
- Joel Epstein, DMD, MSD, Cedars-Sinai, Los Angeles [OMFS]
- Addressing the Psychological Aspects of Head and Neck Cancer
- Elizabeth Cash, PhD, University of Louisville, Louisville, Kentucky [Psychologist]
- The Artistry of Facial Prosthetics
- Devin Okay, DDS, Mount Sinai Hospital, New York [OMFS]
- Nutrition in Head and Neck Cancer
- Patricia Rubio, MBA, MS, University of California, San Diego [Nutritionist]
- Questions and Answers
|
9:50 a.m. - 10:35 a.m. |
Keynote I: Disparities in Head and Neck Cancer
Moderator: Dan Zandberg, MD, University of Pittsburgh Medical Center, Pittsburgh [M]
- Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [R]
- Charles Moore, MD, Emory University, Atlanta [HNS]
|
10:35 a.m. - 11:00 a.m. |
Coffee Break |
11:00 a.m. - 12:30 p.m. |
Escalation Strategies and Novel Approaches in Locally Advanced Head and Neck Cancer
Moderator: Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]
- Immunotherapy in the Curative Intent Setting
- Sana Karam, MD, PhD, University of Colorado, Denver [R]
- The Role of Preop IO in Locally Advanced HNC
- Ravi Uppaluri, MD, PhD, Brigham and Women’s Hospital, Boston [HNS]
- Novel Radiosensitizers
- Heath Skinner, MD, PhD, University of Pittsburgh, Pittsburgh [R]
- Nasopharynx: Induction vs Adjuvant – Where do we go from here?
- Dimitrios Colevas, MD, Stanford University, Stanford, California [M]
- Questions and Answers
|
12:30 p.m. - 1:30 p.m. |
Lunch in the Exhibit Hall
Early-career and Trainee Networking Luncheon: Choosing Your Career Path
Highlight careers briefly at the beginning and then break out into small groups at the different round tables.
Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
- Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]
- Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [Speech Path]
- Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M]
- Loren Mell, MD, University of California, San Diego [R]
- Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
|
1:30 p.m. - 3:00 p.m. |
K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session
Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]
- Early Toxicity and Patient Reported Outcomes from a Phase 2 Trial of FDG-PET Response-based De-escalated Definitive Radiotherapy for p16+ Oropharynx Cancer
- Steven Allen, University of Michigan, Ann Arbor, Michigan
- Non-inferiority Margin and Nodal Analysis of De-escalated Adjuvant Radiation Therapy (DART) for HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675
- Daniel Ma, Mayo Clinic, Rochester, Minnesota
- Detection of Occult Recurrence Using Circulating HPV Tumor DNA among Patients Treated for HPV-driven Oropharyngeal Squamous Cell Carcinoma
- Glenn Hanna, Dana-Farber Cancer Institute, Harvard Medical School, Boston
- Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles from Patients with HPV-positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy
- Michelle Echevarria, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
- A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-associated Head and Neck Cancer with Implications for Treatment Deintensification and Immunotherapy
- Peter Zeng, Western University, London, Ontario, Canada
- Predicted Th2 Infiltrate is Associated with Outcome in HPV(-) Head and Neck Cancer
- Mohamed Abdelhakiem, UPMC Hillman Cancer Center, Pittsburgh
- Loss of HPV 16- E2 Predicts Disease Free Survival and Promotes Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
- Molly Heft-Neal, University of Michigan, Ann Arbor, Michigan
- Neoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model
- Robert Saddawi-Konefka, University of California, San Diego
- HPV E5 Mediates Resistance to PD-1 Checkpoint Blockade via Inhibition of MHC and IFN Pathway
- Andrew Sharabi, University of California, San Diego
|
3:00 p.m. - 3:30 p.m. |
Coffee Break |
3:30 p.m. - 4:30 p.m. |
Case Study and Debate: Curative Intent in Elderly and Frail
Moderator: Zain Husain, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [R]
- Susan McCammon, MD, University of Alabama, Birmingham, Birmingham, Alabama [HNS]
- Loren Mell, MD, University of California, San Diego [R]
- Paul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M]
- Questions and Answers
|
4:30 p.m. - 5:30 p.m. |
Research Feature and Networking Reception |